{
    "clinical_study": {
        "@rank": "60338", 
        "arm_group": {
            "arm_group_label": "ARN-810", 
            "arm_group_type": "Experimental", 
            "description": "During dose escalation, standard 3+3 design will be followed with a starting dose of 100 mg per day, followed by dose escalation to 200 mg, and by 200 mg increments thereafter. During dose expansion, two new cohorts of patients will be enrolled at the MTD/RP2D to further characterize the safety and pharmacokinetics of ARN-810."
        }, 
        "brief_summary": {
            "textblock": "Safety and pharmacokinetics (PK) study of ARN-810 in postmenopausal women with locally\n      advanced or metastatic ER+ (HER2-) breast cancer."
        }, 
        "brief_title": "Study of ARN-810 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Open-label, dose-finding study of ARN-810 administered orally on a continuous daily dosing\n      regimen with a PK lead-in period .  The incidence of dose limiting toxicity (DLT) will be\n      evaluated from Day -7 through the first cycle (28 days) of treatment (35 days total).\n      Depending on safety and tolerability, patients will be assigned sequentially to escalating\n      doses of ARN 810 using standard 3+3 design. All patients will be treated until disease\n      progression, unacceptable toxicity, or patient withdrawal of consent."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Histologically or cytologically proven diagnosis of adenocarcinoma of the breast with\n             evidence of either locally recurrent disease not amenable to resection or radiation\n             therapy with curative intent, or metastatic disease, both progressing after at least\n             6 months of hormonal therapy for ER+ breast cancer\n\n          2. ER-positive, HER2-negative\n\n          3. At least 2 months must have elapsed from the use of tamoxifen\n\n          4. At least 6 months must have elapsed from the use of fulvestrant\n\n          5. At least 2 weeks must have elapsed from the use of any other anti-cancer hormonal\n             therapy\n\n          6. At least 4 weeks must have elapsed from the use of any chemotherapy\n\n          7. Females, 18 years of age or older\n\n          8. Postmenopausal status\n\n          9. Eastern Cooperative Oncology Group (ECOG) Performance status \u2264 2\n\n        Key Exclusion Criteria:\n\n          1. Untreated or symptomatic CNS metastases.\n\n          2. Endometrial disorders\n\n          3. More than 1 prior chemotherapy in the advanced/metastatic setting (prior adjuvant\n             chemotherapy is allowed so long as it occurred \u2265 12 months prior to enrollment)\n\n          4. Current treatment with any systemic anti-cancer therapies for advanced disease or any\n             systemic experimental treatment on another clinical trial"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01823835", 
            "org_study_id": "ARN-810-001"
        }, 
        "intervention": {
            "arm_group_label": "ARN-810", 
            "intervention_name": "ARN-810", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Estrogens"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Locally Advanced or Metastatic ER+ Breast Cancer", 
            "Post-Menopausal", 
            "Oral ER antagonist"
        ], 
        "lastchanged_date": "August 22, 2013", 
        "location": [
            {
                "contact": {
                    "email": "bardia.aditya@mgh.harvard.edu", 
                    "last_name": "Aditya Bardia, MD", 
                    "phone": "617-643-2208"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": {
                    "last_name": "Aditya Bardia, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dicklerm@mskcc.org", 
                    "last_name": "Maura Dickler, MD", 
                    "phone": "646-888-5456"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Maura Dickler, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "shireen.a.williams@vanderbilt.edu", 
                    "last_name": "Shireen Williams", 
                    "phone": "615-875-6278"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt-Ingram Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Ingrid A Mayer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Phase I Study of ARN-810 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer", 
        "overall_official": {
            "affiliation": "Seragon Pharmaceuticals", 
            "last_name": "Edna Chow Maneval, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of ARN-810 in postmenopausal women with locally advanced or metastatic ER+ (HER2-) breast cancer", 
                "measure": "Maximum Tolerated Dose (MTD)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Incidence of treatment-emergent adverse events will be summarized by severity and relationship to study drug.  Clinical laboratory results, vital signs, use of concomitant medications and treatments, and endometrial thickness will be summarized with descriptive statistics (such as mean, median, standard deviation and range for continuous data, and percentages for categorical data).", 
                "measure": "To determine the safety of ARN-810 and its O-glucuronide metabolite in postmenopausal women with locally advanced or metastatic ER+ (HER2-) breast cancer", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01823835"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Full plasma PK profiles (Cmax, Tmax, AUC, T1/2) will be obtained for ARN-810 and its O-glucuronide metabolite and analyzed using non-compartmental methods.", 
            "measure": "Pharmacokinetics (PK) of ARN-810 and its O-glucuronide metabolite", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Seragon Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seragon Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}